Table 3 Hazard ratios (HRs) for ccRCC-related deaths truncated at 10 years of follow-up according to genotypes of ccRCC in the Netherlands Cohort Study on diet and cancer. The FDR-adjusted p-value was calculated using the Benjamini–Hochberg method. The cut-off for a statistically significant p-value and FDR-adjusted p-value is 0.05.

From: Evaluation of a seven gene mutational profile as a prognostic factor in a population-based study of clear cell renal cell carcinoma

Gene mutated

Total no. of cases

No. of ccRCC-related deaths

Survival time, years

Model 1a

Model 2b

Model 3c

p-value

FDR adj. p-value

HR

(95% CI)

HR

(95% CI)

HR

(95% CI)

VHL

No

70

28

399

1

Ref

1

Ref

1

Ref

  

Yes

40

8

233

0.53

(0.24–1.17)

0.33

(0.14–0.79)

0.34

(0.13–0.89)

0.028

0.063

PBRM1

No

84

32

462

1

Ref

1

Ref

1

Ref

  

Yes

26

4

171

0.36

(0.12–1.01)

0.26

(0.08–0.79)

0.17

(0.04–0.66)

0.010

0.063

SETD2

No

98

33

577

1

Ref

1

Ref

1

Ref

  

Yes

12

3

56

1.10

(0.33–3.68)

0.70

(0.16–3.01)

1.04

(0.24–4.45)

0.957

0.957

KDM5C

No

100

33

574

1

Ref

1

Ref

1

Ref

  

Yes

10

3

59

1.22

(0.34–4.37)

1.61

(0.44–5.97)

1.43

(0.37–5.43)

0.598

0.672

BAP1

No

104

35

593

1

Ref

1

Ref

1

Ref

  

Yes

6

1

40

0.41

(0.06–3.01)

0.36

(0.05–2.74)

0.16

(0.02–1.46)

0.104

0.156

TP53

No

107

34

627

1

Ref

1

Ref

1

Ref

  

Yes

3

2

6

5.44

(1.22–24.24)

0.53

(0.09–3.10)

0.43

(0.07–2.86)

0.387

0.498

MTOR

No

108

36

622

1

Ref

1

Ref

1

Ref

  

Yes

2

0

11

N/A

–

N/A

–

N/A

–

–

–

Mutation present in VHL and/or PBRM1

No mutation in VHL and PBRM1

59

25

322

1

Ref

1

Ref

1

Ref

  

Mutation in PBRM1, not in VHL

11

3

67

0.56

(0.17–1.87)

0.28

(0.07–1.11)

0.16

(0.03–0.80)

0.026

0.063

Mutation in VHL, not in PBRM1

25

7

130

0.73

(0.31–1.70)

0.36

(0.14–0.94)

0.32

(0.11–0.94)

0.039

0.063

Mutation in VHL and PBRM1

15

1

103

0.15

(0.02–1.09)

0.08

(0.01–0.67)

0.06

(0.01–0.59)

0.015

0.063

  1. aAdjusted for age at diagnosis (years) and sex.
  2. bAdjusted for age at diagnosis (years), sex, TNM stage, differentiation grade and tumour size.
  3. cAdjusted for age at diagnosis (years), sex, TNM stage, differentiation grade and tumour size and mutually adjusted for the other genes. MTOR was not included in the model due to the absence of fatal events in participants with an MTOR mutation.
Back to article page